ticlopidine has been researched along with Heart Failure in 59 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "By inhibiting prostaglandins, aspirin may be deleterious in heart failure (HF) and/or may counteract angiotensin-converting enzyme (ACE) inhibitor efficacy." | 9.12 | Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. ( Bergmann, JF; Cohen-Solal, A; Duboc, D; Fulla, Y; Mahé, I; Meune, C; Mouly, S; Simoneau, G; Wahbi, K; Weber, S, 2007) |
| "The benefits of taking of aspirin, clopidogrel, and warfarin in relation to cardiovascular mortality and re-hospitalization in chronic heart failure (HF) patients have been called into question." | 7.78 | Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. ( Celikyurt, U; Ertaş, G; Kılıç, T; Kozdağ, G; Sahin, T; Ural, D; Yaymacı, M, 2012) |
| "We studied the association of clopidogrel with mortality in acute myocardial infarction (AMI) patients with heart failure (HF) not receiving percutaneous coronary intervention (PCI)." | 7.76 | Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. ( Abildstrøm, SZ; Bonde, L; Bretler, DM; Fosbøl, EL; Gislason, GH; Hansen, PR; Kober, L; Olesen, J; Schramm, TK; Sorensen, R; Torp-Pedersen, C; Weeke, P, 2010) |
| "The ability of clopidogrel to inhibit platelet function in patients with congestive heart failure (CHF) was proved by the PLUTO-CHF trial." | 7.74 | Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? ( Malinin, AI; O'Connor, CM; Oshrine, BR; Sane, DC; Serebruany, VL, 2007) |
| "Transient pancytopenia as an adverse hematologic reaction due to ticlopidine." | 7.73 | [Transient pancytopenia due to ticlopidine--a case report]. ( Barg, W; Biełous-Wilk, A; Chmielowicz, B; Grabowski, M; Kopec, A; Panaszek, B, 2005) |
| " Chronic use of mild platelet inhibitors could therefore represent an independent avenue to improve morbidity, mortality, and quality of life in this expanding population." | 6.71 | Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. ( Jerome, SD; Lowry, DR; Malinin, AI; Morgan, AW; O'connor, CM; Sane, DC; Serebruany, VL; Steinhubl, SR; Tanguay, JF, 2003) |
| "Our understanding of the pathogenesis of congestive heart failure (CHF) has improved remarkably in recent years." | 6.42 | Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? ( Dzhanashvili, AI; Malinin, AI; O'Connor, CM; Sane, DC; Serebruany, VL, 2003) |
| " In conclusion, clopidogrel improved endothelial function and NO bioavailability in heart failure." | 5.37 | Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. ( Bauersachs, J; Fraccarollo, D; Loch, E; Neuser, J; Pförtsch, S; Schäfer, A; Vogt, C, 2011) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described." | 5.19 | Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. ( Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD, 2014) |
| "By inhibiting prostaglandins, aspirin may be deleterious in congestive heart failure (CHF) and/or partially counteract the efficacy of angiotensin-converting enzyme inhibitors (ACEI)." | 5.12 | Comparative effect of aspirin and clopidogrel on arterial function in CHF. ( Bergmann, JF; Champion, K; Duboc, D; Lévy, BI; Mahé, I; Meune, C; Mourad, JJ; Simoneau, G; Solal, AC; Weber, S, 2006) |
| "By inhibiting prostaglandins, aspirin may be deleterious in heart failure (HF) and/or may counteract angiotensin-converting enzyme (ACE) inhibitor efficacy." | 5.12 | Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. ( Bergmann, JF; Cohen-Solal, A; Duboc, D; Fulla, Y; Mahé, I; Meune, C; Mouly, S; Simoneau, G; Wahbi, K; Weber, S, 2007) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| " Due to previous atrial fibrillation and ischaemic heart disease, this patient was treated with both dabigatran and clopidogrel." | 3.88 | Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel. ( Fredgart, M; Gill, S, 2018) |
| "We conducted a nested case-control study of Ontarians aged 66 years and older treated with clopidogrel between September 1 2003 and March 31 2013 following acute myocardial infarction." | 3.81 | A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. ( Cressman, AM; Fernandes, KA; Gomes, T; Juurlink, DN; Macdonald, EM; Mamdani, MM; Paterson, JM, 2015) |
| "The benefits of taking of aspirin, clopidogrel, and warfarin in relation to cardiovascular mortality and re-hospitalization in chronic heart failure (HF) patients have been called into question." | 3.78 | Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. ( Celikyurt, U; Ertaş, G; Kılıç, T; Kozdağ, G; Sahin, T; Ural, D; Yaymacı, M, 2012) |
| "We studied the association of clopidogrel with mortality in acute myocardial infarction (AMI) patients with heart failure (HF) not receiving percutaneous coronary intervention (PCI)." | 3.76 | Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. ( Abildstrøm, SZ; Bonde, L; Bretler, DM; Fosbøl, EL; Gislason, GH; Hansen, PR; Kober, L; Olesen, J; Schramm, TK; Sorensen, R; Torp-Pedersen, C; Weeke, P, 2010) |
| "The ability of clopidogrel to inhibit platelet function in patients with congestive heart failure (CHF) was proved by the PLUTO-CHF trial." | 3.74 | Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? ( Malinin, AI; O'Connor, CM; Oshrine, BR; Sane, DC; Serebruany, VL, 2007) |
| "Transient pancytopenia as an adverse hematologic reaction due to ticlopidine." | 3.73 | [Transient pancytopenia due to ticlopidine--a case report]. ( Barg, W; Biełous-Wilk, A; Chmielowicz, B; Grabowski, M; Kopec, A; Panaszek, B, 2005) |
| " Chronic use of mild platelet inhibitors could therefore represent an independent avenue to improve morbidity, mortality, and quality of life in this expanding population." | 2.71 | Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. ( Jerome, SD; Lowry, DR; Malinin, AI; Morgan, AW; O'connor, CM; Sane, DC; Serebruany, VL; Steinhubl, SR; Tanguay, JF, 2003) |
| "Our understanding of the pathogenesis of congestive heart failure (CHF) has improved remarkably in recent years." | 2.42 | Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? ( Dzhanashvili, AI; Malinin, AI; O'Connor, CM; Sane, DC; Serebruany, VL, 2003) |
| " In conclusion, clopidogrel improved endothelial function and NO bioavailability in heart failure." | 1.37 | Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. ( Bauersachs, J; Fraccarollo, D; Loch, E; Neuser, J; Pförtsch, S; Schäfer, A; Vogt, C, 2011) |
| "Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs." | 1.37 | Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure. ( Abegunewardene, N; Gori, T; Horstick, G; Kreitner, KF; Lehr, HA; Münzel, T; Schmidt, KH; Schreiber, LM; Vosseler, M, 2011) |
| "Heart failure is a significant public health problem." | 1.36 | Antithrombotic therapies in patients with heart failure: hypothesis formulation from a research database. ( Burton, P; Cheng, M; Griffin, G; Lee, MS; Oppenheimer, L; Plotnikov, AN; Weinstein, R; Yuan, Z; Zhang, J; Zolynas, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.69) | 18.7374 |
| 1990's | 2 (3.39) | 18.2507 |
| 2000's | 24 (40.68) | 29.6817 |
| 2010's | 30 (50.85) | 24.3611 |
| 2020's | 2 (3.39) | 2.80 |
| Authors | Studies |
|---|---|
| Komiyama, M | 1 |
| Agewall, S | 1 |
| Hasegawa, K | 1 |
| Marcano, AL | 1 |
| Lugo, LM | 1 |
| Besteiro, A | 1 |
| Gomez-Lara, J | 1 |
| Roura, G | 1 |
| Fuentes, L | 1 |
| Gracida, M | 1 |
| Teruel, L | 1 |
| Romaguera, R | 1 |
| Sosa, SG | 1 |
| Cequier, Á | 1 |
| Gómez-Hospital, JA | 1 |
| Comin-Colet, J | 1 |
| Ferreiro, JL | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 1 |
| Huber, K | 2 |
| Halvorsen, S | 2 |
| Steg, PG | 1 |
| Van de Werf, F | 2 |
| Armstrong, PW | 4 |
| Consolo, F | 1 |
| Pozzi, L | 1 |
| Sferrazza, G | 1 |
| Della Valle, P | 1 |
| D'Angelo, A | 1 |
| Slepian, MJ | 1 |
| Pappalardo, F | 1 |
| Fredgart, M | 1 |
| Gill, S | 1 |
| Gershlick, AH | 1 |
| Goldstein, P | 1 |
| Wilcox, R | 1 |
| Danays, T | 1 |
| Lambert, Y | 1 |
| Sulimov, V | 1 |
| Rosell Ortiz, F | 1 |
| Ostojic, M | 2 |
| Welsh, RC | 1 |
| Carvalho, AC | 1 |
| Nanas, J | 1 |
| Arntz, HR | 1 |
| Grajek, S | 1 |
| Fresco, C | 1 |
| Bluhmki, E | 1 |
| Regelin, A | 1 |
| Vandenberghe, K | 1 |
| Bogaerts, K | 1 |
| Hildemann, SK | 1 |
| Schulz, C | 1 |
| Fraccarollo, D | 2 |
| Schöpp, C | 1 |
| Flierl, U | 1 |
| Wissel, K | 1 |
| Pelisek, J | 1 |
| Massberg, S | 1 |
| Bauersachs, J | 2 |
| Schäfer, A | 2 |
| Waks, JW | 1 |
| Sabatine, MS | 1 |
| Cannon, CP | 1 |
| Morrow, DA | 1 |
| Gibson, CM | 1 |
| Wiviott, SD | 1 |
| Giugliano, RP | 1 |
| Sloan, S | 1 |
| Scirica, BM | 1 |
| Maggioni, AP | 1 |
| Sandhu, RK | 1 |
| Hohnloser, SH | 1 |
| Pfeffer, MA | 1 |
| Yuan, F | 1 |
| Hart, RG | 1 |
| Yusuf, S | 1 |
| Connolly, SJ | 1 |
| McAlister, FA | 1 |
| Healey, JS | 1 |
| Pacholewicz, J | 1 |
| Kuliczkowski, W | 1 |
| Kaczmarski, J | 1 |
| Zakliczyński, M | 1 |
| Garbacz, M | 1 |
| Zembala, M | 1 |
| Serebruany, V | 1 |
| Cressman, AM | 1 |
| Macdonald, EM | 1 |
| Fernandes, KA | 1 |
| Gomes, T | 1 |
| Paterson, JM | 1 |
| Mamdani, MM | 1 |
| Juurlink, DN | 1 |
| Dias, A | 1 |
| Franco, E | 1 |
| Koshkelashvili, N | 1 |
| Bhalla, V | 1 |
| Pressman, GS | 1 |
| Hebert, K | 1 |
| Figueredo, VM | 1 |
| Otoshi, T | 1 |
| Kataoka, Y | 1 |
| Nakagawa, A | 1 |
| Otsuka, K | 1 |
| Tomii, K | 1 |
| Buck, J | 1 |
| Kaboli, P | 1 |
| Gage, BF | 1 |
| Cram, P | 1 |
| Vaughan Sarrazin, MS | 1 |
| Ozmete, O | 1 |
| Bali, C | 1 |
| Ergenoglu, P | 1 |
| Suner, HI | 1 |
| Aribogan, A | 1 |
| Ghodsizad, A | 1 |
| Badiye, A | 1 |
| Zeriouh, M | 1 |
| Pae, W | 1 |
| Koerner, MM | 1 |
| Loebe, M | 1 |
| Massie, BM | 2 |
| Collins, JF | 2 |
| Ammon, SE | 2 |
| Cleland, JG | 3 |
| Ezekowitz, M | 2 |
| Jafri, SM | 2 |
| Krol, WF | 2 |
| O'Connor, CM | 5 |
| Schulman, KA | 2 |
| Teo, K | 2 |
| Warren, SR | 1 |
| Hoppe, UC | 2 |
| Kan, LP | 1 |
| Chu, KM | 1 |
| Lin, GM | 1 |
| Bonde, L | 1 |
| Sorensen, R | 1 |
| Fosbøl, EL | 1 |
| Abildstrøm, SZ | 1 |
| Hansen, PR | 1 |
| Kober, L | 1 |
| Schramm, TK | 1 |
| Bretler, DM | 1 |
| Weeke, P | 1 |
| Olesen, J | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, GH | 1 |
| Serebruany, VL | 4 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| Yuan, Z | 1 |
| Weinstein, R | 1 |
| Zhang, J | 1 |
| Cheng, M | 1 |
| Griffin, G | 1 |
| Zolynas, R | 1 |
| Plotnikov, AN | 1 |
| Lee, MS | 1 |
| Oppenheimer, L | 1 |
| Burton, P | 1 |
| Pförtsch, S | 1 |
| Loch, E | 1 |
| Neuser, J | 1 |
| Vogt, C | 1 |
| Kukin, M | 1 |
| Messerli, FH | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 1 |
| Al Suwaidi, J | 1 |
| Anderson, FA | 1 |
| Gore, JM | 1 |
| Goldberg, RJ | 1 |
| Kozdağ, G | 1 |
| Yaymacı, M | 1 |
| Ertaş, G | 1 |
| Celikyurt, U | 1 |
| Sahin, T | 1 |
| Kılıç, T | 1 |
| Ural, D | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Abegunewardene, N | 1 |
| Schmidt, KH | 1 |
| Vosseler, M | 1 |
| Kreitner, KF | 1 |
| Schreiber, LM | 1 |
| Lehr, HA | 1 |
| Gori, T | 1 |
| Münzel, T | 1 |
| Horstick, G | 1 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 1 |
| Stankovic, S | 1 |
| Asanin, M | 1 |
| Trifunovic, D | 1 |
| Majkic-Singh, N | 1 |
| Ignjatovic, S | 1 |
| Mrdovic, I | 1 |
| Matic, D | 1 |
| Savic, L | 1 |
| Marinkovic, J | 1 |
| Vasiljevic, Z | 1 |
| Hondo, T | 1 |
| Matsumura, H | 1 |
| Matsuda, K | 1 |
| Iwamoto, A | 1 |
| Eno, S | 1 |
| Kimura, M | 1 |
| Hess, CN | 1 |
| Broderick, S | 1 |
| Piccini, JP | 1 |
| Alexander, KP | 1 |
| Newby, LK | 1 |
| Shaw, LK | 1 |
| Mahaffey, KW | 1 |
| Alexander, JH | 1 |
| Peterson, ED | 1 |
| Granger, CB | 1 |
| Lopes, RD | 1 |
| Han, YL | 1 |
| Zhang, L | 1 |
| Yang, LX | 1 |
| Liu, HL | 1 |
| Qu, P | 1 |
| Li, WM | 1 |
| Jiang, TM | 1 |
| Li, SM | 1 |
| Jing, QM | 1 |
| Zhang, QY | 1 |
| Xu, B | 1 |
| Li, Y | 1 |
| Gao, RL | 1 |
| Turpie, AG | 1 |
| Bahrmann, P | 1 |
| Sigusch, HH | 1 |
| Surber, R | 1 |
| Figulla, HR | 1 |
| Malinin, AI | 3 |
| Dzhanashvili, AI | 1 |
| Sane, DC | 3 |
| Gerschutz, GP | 1 |
| Bhatt, DL | 1 |
| Kindsvater, S | 1 |
| Leclerc, K | 1 |
| Ward, J | 1 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Jessup, DB | 1 |
| Coletti, AT | 1 |
| Muhlestein, JB | 1 |
| Barry, WH | 1 |
| Shean, FC | 1 |
| Whisenant, BK | 1 |
| Jerome, SD | 1 |
| Lowry, DR | 1 |
| Morgan, AW | 1 |
| Tanguay, JF | 1 |
| Steinhubl, SR | 1 |
| Califf, RM | 1 |
| Packer, M | 1 |
| Warren, S | 1 |
| Garcia, S | 1 |
| Canoniero, MJ | 1 |
| Chirinos, JA | 1 |
| de Marchena, E | 1 |
| Salerno, T | 1 |
| Ferreira, A | 1 |
| Meune, C | 2 |
| Mahé, I | 2 |
| Solal, AC | 1 |
| Lévy, BI | 1 |
| Duboc, D | 2 |
| Simoneau, G | 2 |
| Champion, K | 1 |
| Mourad, JJ | 1 |
| Weber, S | 2 |
| Bergmann, JF | 2 |
| Verheugt, FW | 1 |
| Grabowski, M | 1 |
| Barg, W | 1 |
| Biełous-Wilk, A | 1 |
| Kopec, A | 1 |
| Chmielowicz, B | 1 |
| Panaszek, B | 1 |
| Wahbi, K | 1 |
| Fulla, Y | 1 |
| Cohen-Solal, A | 1 |
| Mouly, S | 1 |
| de Silva, R | 1 |
| Nikitin, NP | 1 |
| Witte, KK | 1 |
| Rigby, AS | 1 |
| Loh, H | 1 |
| Nicholson, A | 1 |
| Bhandari, S | 1 |
| Clark, AL | 1 |
| Oshrine, BR | 1 |
| Erdmann, E | 1 |
| Recio-Mayoral, A | 1 |
| Kaski, JC | 1 |
| McMurray, JJ | 1 |
| Horowitz, J | 1 |
| van Veldhuisen, DJ | 1 |
| Remme, WJ | 1 |
| Kirsch, M | 1 |
| Vermes, E | 1 |
| Boval, B | 1 |
| Drouet, L | 1 |
| Loisance, D | 1 |
| Ferguson, JJ | 1 |
| Guazzi, M | 1 |
| Horwich, TB | 1 |
| Fonarow, GC | 1 |
| Nuttall, A | 1 |
| Smith, HJ | 1 |
| Loveday, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| Analysis of the Platelet Activity State in Patients Implanted With Ventricular Assist Device (VAD)[NCT03255928] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-06-29 | Recruiting | |||
| STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction[NCT02777580] | Phase 4 | 609 participants (Actual) | Interventional | 2017-08-01 | Active, not recruiting | ||
| Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial[NCT04717986] | 188 participants (Actual) | Interventional | 2021-01-26 | Completed | |||
| Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.[NCT02090712] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2010-01-31 | Enrolling by invitation | |||
| CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683] | Phase 3 | 1,587 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
6 reviews available for ticlopidine and Heart Failure
| Article | Year |
|---|---|
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Thera | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Ant | 2003 |
[Cardiology 2007].
Topics: Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Cholesterol; Clopidogrel; Coronary Ar | 2007 |
Prevention of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2002 |
12 trials available for ticlopidine and Heart Failure
| Article | Year |
|---|---|
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatin | 2014 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid | 2015 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Oral antiplatelet therapies have no effect on circulating levels of RANTES in patients with coronary artery disease.
Topics: Aged; Angina, Unstable; Chemokine CCL5; Chemokines; Clopidogrel; Coronary Artery Disease; Female; He | 2002 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Cros | 2003 |
Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Flow Cytometry; Heart Failure; Humans | 2003 |
Watching the WATCH trial: the role of sponsors and data monitoring committees.
Topics: Anticoagulants; Aspirin; Clinical Trials Data Monitoring Committees; Clopidogrel; Heart Failure; Hum | 2004 |
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
Topics: Adult; Aged; Anticoagulants; Aspirin; Clopidogrel; Embolism; Female; Heart Failure; Humans; Male; Mi | 2004 |
Comparative effect of aspirin and clopidogrel on arterial function in CHF.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chi-Square Distribution; Clopidogrel; Doubl | 2006 |
Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Aspirin; Clopidogrel; Female; Heart Fa | 2007 |
41 other studies available for ticlopidine and Heart Failure
| Article | Year |
|---|---|
Future of antithrombotic therapy for heart failure with coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Heart Failure; Humans; Ticlopidine | 2022 |
Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease.
Topics: Blood Platelets; Chemokine CX3CL1; Clopidogrel; Coronary Artery Disease; Heart Failure; Humans; Plat | 2020 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
Topics: Aspirin; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combination; Heart Failure; Heart-Assist | 2018 |
Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diag | 2018 |
Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure.
Topics: Adenosine Diphosphate; Animals; Aorta; Cells, Cultured; Chemokine CX3CL1; Clopidogrel; CX3C Chemokin | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Di | 2014 |
Activated Hemostatic Biomarkers in Patients with Implanted Left Ventricle Assist Devices: Are Heparin and/or Clopidogrel Justified?
Topics: Adult; Anticoagulants; Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Fibrin Fibrinoge | 2015 |
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Clopidogrel; Databases, Factua | 2015 |
Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Heart Failure; Hospital Mortality; Hu | 2016 |
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female | 2016 |
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran | 2016 |
Resuscitation experience in a patient with left ventricular assist device.
Topics: Anesthesia, General; Anticoagulants; Capnography; Cardiopulmonary Resuscitation; Clopidogrel; Defibr | 2016 |
Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Heart Failure; Heart-Assist Devices; Humans; Male; Plat | 2016 |
[Cardiology 2009].
Topics: Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Cardiology; Cardiovascular Diseases; Clopidogrel | 2009 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Denmark; Female; Heart Failure; Humans; Ma | 2010 |
Clopidogrel and heart failure survival: missed opportunity or wrong turn?
Topics: Clopidogrel; Denmark; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2010 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Antithrombotic therapies in patients with heart failure: hypothesis formulation from a research database.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohor | 2010 |
Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure.
Topics: Adenylyl Cyclases; Animals; Aorta; Blotting, Western; Clopidogrel; Endothelium, Vascular; Heart Fail | 2011 |
Wireless pulmonary artery haemodynamic monitoring.
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrodes, Implanted; Equipment Design; Female; Heart Failure | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Chi-Square Distribution; Ch | 2012 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Contrast Media; Coronary Angiography; Coronary Stenos | 2011 |
Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Topics: Aged; Angioplasty; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Chemical Analysis; Clo | 2012 |
A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Aspirin; Autoantibodies | 2012 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea | 2012 |
Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Atrial Fibrillation; Cardia | 2003 |
Development of a score to predict the need for coronary artery bypass graft surgery in patients with non-ST segment elevation acute coronary syndromes.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Artery Bypass; Heart Failure; Humans; Logistic Models; | 2004 |
Antithrombotic therapy in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopidogrel; Drug Interactions; H | 2006 |
[Transient pancytopenia due to ticlopidine--a case report].
Topics: Aged; Anti-Bacterial Agents; Female; Fibrinolytic Agents; Heart Failure; Humans; Pancytopenia; Pneum | 2005 |
Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure.
Topics: Aged; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Creatinine; Female | 2007 |
Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Drug Evaluation; Female; Heart Failure; H | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as | 2007 |
[Four years of circulatory support with the INCOR axial pump from Berlin Heart].
Topics: Clopidogrel; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Heart Failure; Heart-Assist Devic | 2007 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo | 1999 |
Hemodynamic interaction of aspirin with enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Enalapril; Heart Failure; Hemodynamics; Humans; P | 1999 |
A clinically relevant model of heart failure: effects of ticlopidine.
Topics: Animals; Blood Pressure; Coronary Circulation; Disease Models, Animal; Embolism; Female; Heart Failu | 1985 |